New results from VOICE associates tenofovir gel use with lower HSV-2 risk in women

New results from VOICE associates tenofovir gel use with lower HSV-2 risk in women

The unnamed gentleman has filed a lawsuit against the unidentified woman asking for the large sum to compensate for the “pain and suffering” she’s caused by passing the sexually transmitted disease following their hook-up. Tanzania is one of the countries within sub-Saharan Africa severely affected by the HIV epidemic, with an estimated 1.5 million people living with HIV at the end of 2010 [1]. By now you might already know how common herpes is. Usually it is located in S2-4 dermatome and the prognosis for acute urinary retention is benign resolving in about 20 days. Women are especially susceptible to infection because it is more easily transmitted from an infected man to his female sex partner than from a woman to a man. Melvin claims Pavlot gave differing accounts of her medical condition and stress in Melvin’s preliminary hearing and the herpes lawsuit. The results, which were based on an analysis of data involving more than 500 women in VOICE, were reported at the HIV Research for Prevention (HIV R4P) meeting in Cape Town today.

Jeanne Marrazzo, M.D., M.P.H., from the University of Washington, presented the results on behalf of the VOICE study team. Male circumcision is another proven HIV prevention method but there is no evidence that this is effective in reducing transmission from men to women [9]. Many women just like you are able to feel good about themselves again, find acceptance from others, and place herpes exactly where it should be—just one small part of the many characteristics that make up you. Drug was detected in less than a third of blood samples from women who were assigned to use either of the ARV tablets and in less than a quarter of samples from women asked to use tenofovir gel. While the main questions VOICE was designed to ask concerned prevention of HIV, the team amended the protocol to explore whether any of these products also helped to protect women from acquiring HSV in response to results from another study called CAPRISA 004. CAPRISA 004 found tenofovir gel used before and after sex reduced the risk of HIV by 39 percent, a finding that was considered a major milestone for the field. But the study of 889 women in South Africa unexpectedly found that tenofovir gel also reduced the risk of HSV-2 by 51 percent compared to placebo, the first time that any kind of biomedical prevention method was shown to be effective against HSV-2.

New results from VOICE associates tenofovir gel use with lower HSV-2 risk in women
There was very little difference in rates of HSV-2 acquisition between the tenofovir gel and placebo gel groups in VOICE, most likely because adherence to product use in the trial was low overall, Dr. All participants received detailed information about the study to ensure that they understood why the study was being carried out, what the study involved and the involvement of the three collaborating research institutions. I hold a master’s degree in clinical mental health counseling and am a certified holistic health coach. “In this closer examination, we saw tenofovir gel was associated with a significant reduction in HSV-2 risk. The difference was actually quite profound between the two groups of women – those who used the gel and those who hadn’t,” commented Dr. Marrazzo, who led the VOICE study with Zvavahera Mike Chirenje, University of Zimbabwe-University of San Francisco (UZ-UCSF). Women who used the gel regularly were 46 percent less likely to acquire HSV-2 compared to women who seldom or never used the gel (who had no detectable drug in their blood samples), a finding that was statistically significant and was adjusted to account for other potential risk factors, including age, marital status and number of sex partners.

There were 1,004 women in VOICE who had been assigned to use tenofovir gel, 566 of whom were HSV-2 negative at the time they enrolled. Shinyanga, Kahama and Moshi are also along major highways connecting northern Tanzania with the capital city of Dar es Salaam and other countries in the East African region, while Moshi, on the slopes of Mount Kilimanjaro, is also a major destination for international tourism and has a high number of hotels and guesthouses. Melissa King holds an M.S.Ed. Accordingly, HSV-2 incidence was 20.2 percent in women who didn’t use the gel compared to 11.6 percent in women who did. Dr. Marrazzo cautioned that while the results are very encouraging, additional data is still needed. FACTS 001, a Phase III trial that tested tenofovir gel used before and after sex (the same regimen as in CAPRISA 004), was designed specifically to determine whether the gel was safe and effective in reducing the risk of HSV-2 as well as HIV among 2,059 women in South Africa.

Those results are anticipated to be available early 2015. We enrolled HIV-negative women, although some HIV-positive women were enrolled at the Moshi site for a separate sub-study to investigate the molecular epidemiology of HIV. National Institutes of Health. The study products were provided by Gilead Sciences, Inc., of Foster City, Calif., and by CONRAD, of Arlington, Va. Viread (oral tenofovir) and Truvada are registered trademarks of Gilead Sciences. In 2006, Gilead assigned a royalty-free license for tenofovir gel to CONRAD and the International Partnership for Microbicides of Silver Spring, Md. The Microbicide Trials Network (MTN) is an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S.

National Institutes of Health. Information about alcohol use, including screening for problem drinking, was obtained using CAGE [11] and Alcohol Use Disorders Identification Test (AUDIT) [12] questionnaires. More information about the MTN is available at

You may also like